2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Immunology, Immunodeficiency, Infectious Diseases, Viral, Bacterial, Fungal, Other Pathogens, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6266 Most of the black-white and hispanic-white survival deficit in AYA acute lymphoblastic leukemia accrues after the first year: A population-based conditional relative survival analysis of 5,321 patients

Arthur Takao Bookstein, MD, MPH, Justine Po, MD2
1 Tulane University School of Medicine, New Orleans, Louisiana, United States
2 Tulane University School of Medicine, New Orleans, Louisiana, United States

Inferior survival among Black and Hispanic adolescents and young adults (AYA, 15-39y) with acute lymphoblastic leukemia (ALL) is well documented, but when in the disease course these gaps arise has not been characterized in this age group. Distinguishing early (diagnostic delay, induction toxicity, access to care) from late (maintenance continuity, relapse, salvage) contributions has direct implications for intervention design. Population-based work localizing the Black-White gap beyond the first year is limited to children aged 0-14.

We identified patients aged 15-39 diagnosed with ALL as a first or only malignant primary in SEER 17 Registries (Nov 2025 submission), 2000-2018, with follow-up through December 2023 to allow at least 5 years of potential follow-up. Of 5,517 eligible cases, 196 with unknown survival time or death-certificate-only reporting were excluded, leaving 5,321. Actuarial relative survival (RS) used the Ederer II method with US life tables by age, sex, calendar year, race and ethnicity (non-Hispanic White [NHW], Black [NHB], American Indian/Alaska Native [NHAIAN], Asian/Pacific Islander [NHAPI], and Hispanic), and state-county socioeconomic status. Where interval RS exceeded 1, SEER*Stat's non-increasing constraint was applied; this affected NHAIAN, NHB, and NHAPI but no Hispanic or NHW estimate reported here, and can only lower a late estimate. We estimated cumulative RS through 60 months and 5-year RS measured from diagnosis among patients alive at 12 months (conditional RS). Because 5-year RS is the product of 12-month RS and conditional RS, the deficit versus NHW partitions exactly at 12 months into a first-year component (the 12-month RS difference weighted by NHW conditional survival) and a late remainder. Differences were tested by two-sided z test on independent estimates.

Among 5,321 patients (5,303 with known race/ethnicity: Hispanic 2,452; NHW 2,023; NHAPI 433; NHB 338; NHAIAN 57), 5-year RS was 65.5% (95% CI 63.4-67.6) in NHW, 63.9% (59.1-68.3) in NHAPI, 53.7% (51.7-55.7) in Hispanic, and 51.3% (45.8-56.5) in NHB patients. The deficit versus NHW was 14.3 points (8.5-20.0, p<0.001) for NHB and 11.8 points (8.9-14.7, p<0.001) for Hispanic patients; the NHAPI deficit was 1.6 points (-3.4 to +6.7, p=0.53). Partitioning at 12 months attributed 10.7 and 8.3 points respectively to the period after month 12, approximately three-quarters and 70% of each deficit; it is reported only for NHB and Hispanic, whose deficits are large enough to partition stably. By 12 months, RS was 85.5% NHW, 84.9% NHAPI, 80.9% Hispanic, and 80.8% NHB, a roughly 32% relative excess in 12-month mortality for NHB and Hispanic patients. Conditional 5-year RS diverged: NHW 76.6% (74.5-78.6), NHAPI 75.2% (70.4-79.4), Hispanic 66.4% (64.2-68.5), NHB 63.4% (57.3-68.9). Excess mortality peaked between months 12 and 24 (interval RS ratio vs NHW: NHB 0.90, Hispanic 0.94, NHAPI 0.99). NHAIAN patients (n=57) had the largest deficit (15.9 points, 2.6-29.2), but it was predominantly first-year (12-month RS 70.4%, conditional 70.5%), the reverse of the pattern above; this stratum is too small to interpret further.

Most of the Black-White and Hispanic-White survival deficit in AYA ALL accrues after the first year, with the greatest excess mortality between months 12 and 24, though a meaningful first-year gap is also present. This timing implicates relapse incidence and post-relapse salvage as principal targets, consistent with Children's Oncology Group data showing racial and ethnic differences in post-relapse survival and time to relapse. Relapse-associated genomic subtypes plausibly contribute: CRLF2 rearrangement and Ph-like ALL are enriched among Hispanic patients and carry inferior outcomes. Conservatively, expected survival came from life tables specific to race, ethnicity, and state-county socioeconomic status, removing background mortality differences. Censoring within 60 months was more frequent in Hispanic (6.7%) and NHAPI (3.9%) than NHW (1.7%) patients, which biases against detecting a late deficit; NHB censoring was 1.5%. The Hispanic deficit required no non-increasing adjustment and partitions the same way, so the finding does not rest on the adjusted NHB estimates. SEER cannot distinguish biologic from care-delivery contributions; regimen, adherence, lineage, and insurance data are unavailable, and estimates are unadjusted for sex, age, diagnosis era, and disease biology.

Arthur Takao Bookstein, MD, MPH: No relevant conflicts of interest to declare.